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Objectives
To evaluate the activity of intravesical mitomycin-C (MMC)
to ablate recurrent low-risk non-muscle-invasive bladder
cancer (NMIBC) and assess whether it may enable patients to
avoid surgical intervention for treatment of recurrence.
Patients and Methods
CALIBER is a phase II feasibility study. Participants were
randomized (2:1) to treatment with four once-weekly MMC 40-
mg intravesical instillations (chemoablation arm) or to surgical
management. The surgical group was included to assess the
feasibility of randomization. The primary endpoint was
complete response to intravesical MMC in the chemoablation
arm at 3 months, reported with exact 95% confidence intervals
(CIs). Secondary endpoints included time to subsequent
recurrence, summarized by Kaplan–Meier methods.
Results
Between February 2015 and August 2017, 82 patients with
visual diagnosis of recurrent low-risk NMIBC were enrolled
from 24 UK hospitals (chemoablation, n = 54; surgical
management, n =28). The median follow-up was 24 months.
Complete response at 3 months was 37.0% (20/54; 95% CI
24.3–51.3) with chemoablation and 80.8% (21/26; 95% CI 60.6–
93.4) with surgical management. Amongst patients with
complete response at 3 months, a similar proportion was
recurrence-free by 12 months in both groups (84%). Amongst
those with residual disease at 3 months, the 12-month
recurrence-free proportion was lower in the surgical
management group (40.0%) than in the chemoablation group
(84%). Recruitment stopped early as chemoablation did not
meet the prespecified threshold of 45% complete responses at
3 months.
Conclusion
Intravesical chemoablation in low-risk NMIBC is feasible and
safe, but did not demonstrate sufficient response in the
present trial. After chemoablation there may be a reduction
in recurrence rate, even in non-responders, that is greater
than with surgery alone. Further research is required to
investigate the role and optimal schedule of neoadjuvant
intravesical chemotherapy prior to surgery for NMIBC.
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Introduction
Bladder cancer is the ninth most common cancer
worldwide [1], and most frequently presents as non-muscle-
invasive bladder cancer (NMIBC). Approximately 50% of
patients with bladder cancer have low-risk NMIBC [2],
with a 0.8–6% risk of progression to muscle-invasive
disease or bladder cancer death within 5 years and a
relatively high rate of local recurrence, 46–62% [2-4]. Half
of recurrences occur within the first year of follow-up [5].
The discomfort and inconvenience of managing NMIBC
recurrence, combined with cost, are the key issues for
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patients and healthcare providers managing low-risk
NMIBC [6-8].
Guidelines recommend annual cystoscopy for 5 years for low-
risk NMIBC [2]. Treatments for local recurrence include
transurethral resection and cystodiathermy under general
anaesthesia, laser ablation under local anaesthesia and
watchful waiting [9,10]. This variety reflects the indolent
nature of low-risk NMIBC and lack of high-quality evidence
about the optimal management.
Several small studies have demonstrated promising results for
intravesical chemotherapy alone (chemoablation) as an
alternative to surgical management for NMIBC. The optimal
schedule and its effectiveness in achieving a complete
response in low-risk NMIBC are unclear. Reviews of
chemoablation (including >1200 patients with varying risk
and different chemotherapy regimens) suggest the complete
response rate is ~50%, with the therapeutic effect sustained
for at least 2 years [11,12]. These data suggest chemoablation
may be a viable treatment for low-risk NMIBC.
To inform trial design, 100 patients undergoing surveillance
for low-risk NMIBC were surveyed. They had concerns
regarding inpatient surgical management of recurrence under
general anaesthesia and stated a preference for a non-surgical
outpatient option. A focus group of patients with NMIBC
was then held to discuss potential trial designs, at which,
based on available data [11,12], chemoablation was confirmed
as an attractive alternative to surgical management for
recurrent low-risk NMIBC, and suitable success criteria for a
phase II trial were agreed.
CALIBER was therefore developed to investigate intravesical
chemoablation as an alternative to surgical management for
recurrent low-risk NMIBC, incorporating patient-reported
outcomes to assess the acceptability to participants of the
treatments.
Patients and Methods
Trial Design, Management and Governance
CALIBER (NCT02070120) is a phase II multicentre feasibility
study. A two-stage randomized design was used to establish
the chemoablation response rate whilst obtaining prospective
surgical management data and assessing the feasibility of
randomization to treatments for any subsequent comparative
trial. Recruitment was planned to continue seamlessly
between stages 1 and 2.
The trial was approved by the Medicines and Healthcare
Products Regulatory Authority and South Central –
Hampshire-B Research Ethics Committee (ref: 14/SC/1223,
approved 29 August 2014), sponsored by The Institute of
Cancer Research (ICR) and conducted according to the
principles of good clinical practice. The Clinical Trials and
Statistics Unit at the ICR (ICR-CTSU) co-ordinated the
study and data collection, and conducted statistical analysis.
The trial management group was overseen by independent
data monitoring and trial steering committees.
Patients
Eligible patients had previously diagnosed, histologically
confirmed, low-risk NMIBC with visual diagnosis of
recurrence. Patients were aged >16 years, with an European
Organisation for Research and Treatment of Cancer
(EORTC) risk of recurrence score ≤6 [2] (this criterion was
revised in December 2016 from ≤5, as a result of inadvertent
exclusion of patients for whom chemoablation may be an
appropriate treatment option), with no history of high grade/
≥T1 or non-urothelial bladder cancer. Patients with prior
treatment of the recurrence or contraindication to trial
treatment were excluded. All participants provided written
informed consent.
Treatment Allocation and Study Procedures
Patients were recruited at UK NHS hospitals and
allocated by the ICR-CTSU to either chemoablation or
surgical management in a 2:1 ratio. Treatment allocation
was by minimization with a random element, with
balancing factors of treating site and recurrence history
(first or further recurrence). Treatment allocation was not
blinded.
Patients in the chemoablation group received four once-
weekly intravesical instillations of 40 mg mitomycin-C
(MMC) as outpatients, in accordance with local policy. No
dose reductions were permitted. Patients assigned to surgical
management underwent the local standard technique for
treatment of recurrence; a single instillation of 40 mg MMC
within 24 h postoperatively was permitted.
A cystoscopy was conducted 3 months after treatment
completion to assess response visually and to biopsy the
tumour bed. Subsequent cystoscopic follow-up was at 6 (if
disease detecded at 3 months) and 12 months after treatment,
and annually thereafter.
Outcomes
The primary endpoint was complete response to
chemoablation at 3 months post-treatment, defined as an
absence of any bladder tumour both by visual assessment and
biopsy.
Secondary endpoints included time from end of treatment to
subsequent recurrence, subsequent transurethral resection of
bladder tumour (TURBT)/biopsy rates after the 3-month
disease assessment, safety, and patient-reported health-related
quality of life (HRQoL) outcomes.
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Adverse events were assessed at end of treatment and at
3 months, using National Cancer Institute Common
Terminology Criteria for Adverse Events (CTCAE) version
4.0. HRQoL was assessed with the EORTC’s general quality-
of-life questionnaire, the QLQ-C30 [13], and the NMIBC-
specific module (QLQ-NMIBC24) [14]. The primary objective
of the HRQoL study was to assess differences between groups
in the global quality-of-life scale of the QLQ-C30.
Questionnaires were completed by patients at baseline, 3, 6
and 12 months.
Statistical Considerations
CALIBER was designed to exclude a complete response rate
of <45% in the chemoablation group. Using a Simon two-
stage optimal design [15], complete response in at least 26/51
chemoablation patients was required in stage 1. Prior to stage
1 analysis, the design was adapted to reduce stage 2 sample
size and remove the randomization (Data S1). In the revised
design, with 85% power and an a value = 0.10, complete
response in at least 31/60 chemoablation patients was
required at the end of stage 2. The total target recruitment
was 89 patients, 63 patients in the chemoablation group
(accounting for 5% non-compliance) and 26 in the surgical
management group (stage 1 control group).
Efficacy outcomes were analysed on the evaluable population,
i.e. patients with 3-month assessment data who received their
allocated treatment. Sensitivity analyses on the per-protocol
and eligible populations were performed (Table S1). Safety
analyses were conducted according to treatment received.
Complete response rate was calculated based on (i) no disease
on visual assessment at 3-month cystoscopy, and (ii) where 3-
month biopsy was performed, no disease on histopathology
assessment. Patients with visually detected disease, or positive
histology when visually clear, were classified as not
responding. Both definitions were considered for the stage 1
stop/go decision. Complete response rates were presented
with exact binomial 95% CIs. The trial was not powered for
the direct comparison of complete response rate between
treatment groups and no formal statistical comparisons of the
primary endpoint were planned.
Time to first subsequent recurrence after response status
assessment at 3 months was summarized using Kaplan–Meier
methods, and treatment groups were compared by the
stratified log-rank test, adjusting by response status at
3 months. The four groups defined by the combination of
treatment and response status at 3 months were compared
using the log-rank test. Frequency of subsequent NMIBC
recurrence/TURBT was summarized by treatment; worst
CTCAE grade adverse event was summarized by timepoint
and treatment received. Treatment comparisons used chi-
squared or Fisher’s tests as appropriate. Statistical
comparisons for the secondary endpoints were considered
exploratory.
Standard algorithms were used to derive scores from and
handle missing HRQoL data [16]. Change from baseline was
calculated and summarized descriptively at each subsequent
timepoint, with means and 99% CIs. A larger confidence level
was chosen for HRQoL endpoints to account for multiplicity
across subscales and timepoints.
Analyses were based on a data snapshot taken on 10 October
2018, triggered once all patients had at least 12 months of
follow-up (or earlier if lost to follow-up), and performed using
STATA version 15.0 (StataCorp LLC, College Station, TX) [17].
Results
Participants
Eighty-two patients were enrolled in the study
(chemoablation, n = 54; surgical management, n =28) from
24 UK sites between February 2015 and August 2017 (Fig. 1).
Fifty-six percent (82/145) of eligible patients reported on
sites’ screening logs consented to participation. CALIBER
ceased recruitment in August 2017, after the Independent
Data Monitoring Committee concluded the trial should stop
for futility based on stage 1 complete response rates.
Baseline features were evenly matched across treatment
groups (Table 1). In the chemoablation group, 53 patients
(98%) received all four planned instillations, with one patient
receiving three. In the surgical management group, 27
patients received surgery, of whom 16 (57%) received
diathermy (Table 2).
Response Rates
The stage 1 stop/go decision was based on the first 51
evaluable chemoablation patients: 18 complete responses were
reported by visual and histopathology assessment (where
available) with 23 complete responses reported by visual
assessment alone. The criterion to proceed to stage 2 was not
met by either definition of complete response.
Complete response rate in the chemoablation group overall
was 37% (20/54; 95% CI 24–51) by visual and histopathology
assessment and 48% (26/54; 95% CI 34–62) by visual
assessment alone. Complete response rate was 81% (21/26;
95% CI 61–93) in the surgical management group by visual
and histopathology assessment.
Figure 2 shows the concordance between visual and
histopathology assessment. In the chemoablation group, 28/54
patients (52%) had visible disease at 3 months (no complete
response), with 23/28 confirmed histologically. Of 26/54
patients (48%) with no visible disease, 6/26 had disease
© 2020 The Authors
BJU International published by John Wiley & Sons Ltd on behalf of BJU International 819
Chemoablation for low risk bladder cancer
Randomized
n=82
Chemoablation
n=54
Surgery
n=28
Received allocated 
treatment
n=54
Received allocated 
treatment
n=27
3-month assessment 
available
n=54
3-month outcome known
n=26
Treatment
Analysis
1 withdrew consent 
after randomization
1 lost to follow-up 
Allocation
Found ineligible after 
randomisation n=3
Found ineligible after 
randomisation n=6
Fig. 1 CONSORT diagram. Eighty patients were included in the primary and efficacy endpoints’ analysis: two patients without a 3-month assessment in
the surgical management group were excluded (one withdrew from trial treatment after randomization, one was lost to follow-up before 3 months). All
patients for whom there were completed post-treatment and/or 3-month adverse event forms were included in the safety analyses (N = 81). Nine
patients (three surgical management, six chemoablation) were found ineligible after randomization but were included in all analyses in accordance
with the CALIBER Statistical Analysis Plan.
Table 1 Baseline characteristics of CALIBER participants.
Surgical management group (N = 28) Chemoablation group (N = 54) All patients (N = 82)
Gender, n (%)
Male 23 (82.1) 40 (74.1) 63 (76.8)
Female 5 (17.9) 14 (25.9) 19 (23.2)
Age, years
Mean (SD) 69.3 (11.5) 73.4 (7.6) 72.0 (9.2)
Median (Q1–Q3) 70.7 (61.1–77.1) 72.5 (68.8–78.3) 72.4 (66.8–77.9)
Number of tumours at trial entry, n (%)
1 21 (75.0) 47 (87.0) 68 (82.9)
2–7 7 (25.0) 7 (13.0) 14 (17.1)
Maximum tumour diameter at trial entry, n (%)
<3 cm 27 (96.4) 54 (100.0) 81 (98.8)
≥3 cm 1 (3.6) 0 (0.0) 1 (1.2)
Recurrence rate at trial entry, n (%)
≤1 year 27 (96.4) 49 (90.7) 76 (92.7)
>1 year* 1 (3.6) 5 (9.3) 6 (7.3)
Number of previous occurrences of NMIBC†, n (%)
1 15 (53.6) 30 (55.6) 45 (54.9)
2 8 (28.6) 12 (22.2) 20 (24.4)
3 4 (14.3) 4 (7.4) 8 (9.8)
4 0 (0.0) 3 (5.6) 3 (3.7)
≥5 1 (3.6) 5 (9.3) 6(7.3)
Prior MMC (single instillation) , n (%)
Yes 19 (67.9) 33 (61.1) 52 (63.4)
No 8 (28.6) 18 (33.3) 26 (31.7)
Unknown 1 (3.6) 3 (5.6) 4 (4.9)
Grade at original diagnosis, n (%)
G1 15 (53.6) 22 (40.7) 37 (45.1)
G2 13 (46.4) 32 (59.3) 45 (54.9)
Risk score at trial entry, n (%)
2 10 (35.7) 21 (38.9) 31 (37.8)
3 10 (35.7) 24 (44.4) 34 (41.5)
5 5 (17.9) 3 (5.6) 8 (9.8)
6 2 (7.1) 3 (5.6) 5 (6.1)
8* 1 (3.6) 3 (5.6) 4 (4.9)
MMC, mitomycin C; NMIBC, non-muscle-invasive bladder cancer; Q1, first quartile, 25% percentile; Q3, 3rd quartile, 75% percentile. *Patients found ineligible after randomization,
due to incorrect calculation of the risk score at site. †Including diagnosis; overall (since diagnosis).
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confirmed on biopsy. In the surgical management group, 3/26
patients (12%) had visible disease at 3 months, all confirmed
histologically; 2/23 patients with no visible tumour had
residual disease confirmed on biopsy. Three-month histology
was unavailable for nine patients in the chemoablation group
and 11 in the surgical management group. Table 3
summarizes disease found at 3 months.
Recurrences Subsequent to the 3-Month Disease
Assessment
With a median (interquartile range) follow-up at time of data
snapshot of 24 (15–29), months, 27 patients had NMIBC
recurrences after their 3-month disease assessment. In the
chemoablation group, 16 patients (30%) had at least one
NMIBC recurrence, with two (4%) experiencing more than
one. Eleven surgical management patients (39%) had at least
one subsequent NMIBC recurrence, with four (14%)
experiencing more than one. Five chemoablation patients
(9%) and six surgical management patients (21%) underwent
TURBT. No statistically significant differences were found
between the groups.
One patient had a second primary cancer diagnosed before
their NMIBC recurrence and was censored in the analysis of
time to first post-3 month recurrence. No significant
difference was observed between treatment groups in
recurrence rates over time (Fig. 3A). When explored by
disease status and treatment at 3 months (Fig. 3B), surgical
management patients with disease at 3 months did
significantly worse, while the proportion free of subsequent
recurrence at 12 months was similar in patients who
underwent surgery and were disease-free at 3-months and in
the chemoablation group, with or without disease at 3
months (P = 0.01).
Progression Rate and Overall Survival
No patient experienced disease stage progression, although
five patients had grade progression to carcinoma in situ and/
or G3Ta at 3 months (Table 3). Two patients (one in each
group) died during follow-up, both from cardiac events not
considered disease-related; both had complete response at
3 months.
Table 2 Surgical management group: details of surgical technique and
histology at trial entry.
Surgical management
group (N = 28)
Type of surgery, n(%)
Diathermy 16(57.1)
TURBT 12(42.9)
Single postoperative MMC instillation given, n(%)
Yes 3(10.7)
Stage*, n(%)
Benign 3(10.7)
Ta 18(64.3)
Grade*, n(%)
Benign 3(10.7)
G1 6(21.4)
G2 11(39.3)
GX 1(3.6)
MMC, mitomycin-C; TURBT, transurethral resection of bladder tumour. * Only 21
with histological confirmation.
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Fig. 2 Response at 3-month assessment: visual vs histological confirmation.
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Safety and Tolerability
Post-treatment adverse event data were available for 81
patients. No serious adverse events or grade 3–4 adverse
events were reported. Grade 2 adverse events were reported
for 14/81 patients (17%), and for 29/81 patients (36%) a
worst grade of 1 was reported. No differences between groups
were found (Tables S2–S4). In the surgical management
group, 7/28 patients (25%) experienced complications prior to
discharge from surgery, mostly haematuria (six patients;
21%).
Health-Related Quality of Life
Seventy-eight patients consented to participate in the optional
HRQoL sub-study (51 in the chemoablation, 27 in the
surgical management group). The two treatment groups
exhibited similar HRQoL throughout follow-up, both in
global quality of life and other key subscales of interest
(Figs 4 and S1, S2).
Discussion
We demonstrated the feasibility of randomization between
surgical and medical management of low-risk NMIBC.
Chemoablation with four MMC instillations was well
tolerated. The predefined criterion for progression to stage 2
was not met and the trial closed early, but a sustained
reduction in recurrence rate was suggested. HRQoL was not
substantially impacted by either treatment.
To our knowledge, this is the first study to measure the effect
of chemoablation using histological rather than visual criteria.
Complete response rates in both groups were lower than
expected when compared to previous studies reporting visual
complete response only [11,12]. Based on our findings, visual
complete response should be used with caution as a primary
endpoint in NMIBC trials, although its pragmatic use in a
clinical setting is probably acceptable.
At 12 months, recurrence rate was similar between patients
with complete response at 3 months in both groups (16%).
Table 3 Three-month assessment: details of surgical technique and histology.
Surgical
management
group
Chemoablation
group
All patients
n(%) n(%) n(%)
Patients with disease present at 3 months
(visual and histologically, where available)
5(100) 34(100) 39(100)
Treatment for residual disease
Diathermy 1(20) 11(32.4) 12(30.8)
TURBT 3(60) 19(55.9) 22(56.4)
Biopsy alone 1(20) 3(8.8) 4(10.3)
Cystoscopy alone 0(0) 1(2.9) 1(2.6)
Single postoperative MMC instillation given
Yes 0(0) 2(5.9) 2(5.1)
Number of tumours
1 5(100) 20(58.8) 25(64.1)
2–7 0(0) 12(35.3) 12(30.8)
Unknown 0(0) 2(5.9) 2(5.1)
Maximum tumour diameter
<3 cm 4(80) 29(85.3) 33(84.6)
≥3 cm 1(20) 2(5.9) 3(7.7)
Unknown 0(0) 3(8.8) 3(7.7)
Stage
Benign 0(0) 3(8.8) 3(7.7)
Ta 5(100) 27(79.4) 32(82.1)
Ta + CIS 0(0) 1(2.9) 1(2.6)
CIS 0(0) 1(2.9) 1(2.6)
Unknown 0(0) 2(5.9) 2(5.1)
Grade
Benign 0(0) 3(8.8) 3(7.7)
G1 0(0) 10(29.4) 10(25.6)
G2 4(80) 13(38.2) 17(43.6)
G3 1(20) 3(8.8) 4(10.3)
GX 0(0) 1(2.9) 1(2.6)
Unknown 0(0) 4(11.8) 4(10.3)
Disease location
Same as trial entry 5(100) 32(94.1) 37(94.9)
Different location 0(0) 2(5.9) 2(5.1)
CIS, carcinoma in situ; MMC, mitomycin-C, TURBT, transurethral resection of bladder tumour.
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Rates were also similar in patients who ‘failed’ chemoablation
and were ‘salvaged’ by surgical management at 3 months. By
contrast, patients who ‘failed’ surgical management without
prior intravesical chemoablation had a 12-month recurrence
rate of 60%, although caution is needed because of the small
size of the groups.
The use of four instillations of MMC was chosen
pragmatically to fit into the UK national 31-day target for
cancer surgery and avoid delaying surgery if there was no
response. A more intensive or extended regimen may result
in improved response rates and any further research should
consider this. Our results suggest that four MMC instillations
12−months %: 75.4% vs 82.7% 
Stratified Hazard Ratio 0.44 (95%CI 0.17−1.15)
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Fig. 3 Kaplan–Meier estimate of proportion of patients free of subsequent recurrence after 3-month disease assessment, by allocated treatment (A)
and by allocated treatment and disease status (B). Patients who had a second primary cancer or died for reasons other than bladder cancer without
a prior recurrence were censored at date of second primary or date of death. Stratified log-rank test and stratified Cox model to explore the differences
between treatment groups were used as appropriate to account for disease response status at 3 months (A). When treatment and disease status were
combined to form four groups, these were compared by log-rank test (not stratified). Proportional hazards were tested using Schoenfeld residuals.
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may have some chemo-protective effect against low-risk
NMIBC recurrence. There remains a group of frail patients
who tolerate surgery poorly, for whom a near 50% chance of
complete ablation of visible tumours may be beneficial in
terms of safety and improved quality of life.
A particular challenge for trials in low-risk NMIBC is that
the diagnosis can only be confirmed after tissue examination
from TURBT; therefore, we could only recruit patients with a
previous low-risk NMIBC diagnosis who had experienced
recurrence. To ensure consistency in definition of low-risk
NMIBC across multiple hospitals we used the EORTC risk
score tables [18] rather than the NMIBC guideline risk
categories of the European Association of Urology (EAU) [2].
These constraints had important consequences; although 50%
of newly diagnosed patients with NMIBC are low risk, over
two-thirds never have any subsequent recurrence [2], whilst
those that do (those eligible for this study) are re-classified as
intermediate-risk patients, both according to EAU guidelines
and the EORTC risk tables. The results should therefore be
interpreted in this context.
The trial has a number of weaknesses. It was not powered for
direct comparison of response rate between randomized
groups, limiting ability to definitively identify differences
between treatments. The study population probably reflects a
group of patients with intermediate-, rather than low-risk
NMIBC, limiting ability to extrapolate results to newly
diagnosed low-risk NMIBC. To assess potential comparators
for phase III, the control arm permitted different surgical
options, including biopsy with diathermy, potentially
underestimating the benefits of an expertly conducted
TURBT. Only three patients in the surgical group (11%)
received a postoperative MMC instillation; had all patients in
the surgical management group received this, the observed
complete response to surgery may have been higher and the
subsequent recurrence rate reduced. Finally, there was
relatively poor compliance with the biopsy at 3 months, so
visual assessment of response was not verified by histology
for every patient.
Alternative strategies for managing low-risk NMIBC include
active surveillance [9] and office fulguration. Whilst active
surveillance appears safe, our patient focus group indicated
this was not a popular strategy. Office fulguration is popular
in some countries because it avoids general anaesthesia and is
therefore cost-effective, but it is not popular amongst patients
in the UK and is often painful, particularly for elderly
patients. Moreover, in the surgical arm of CALIBER, 57% of
patients had fulguration (rather than TURBT) and nearly
20% had residual disease at 3 months, which calls into
question the effectiveness of using this strategy alone.
Ultimately, all three strategies have an important role to play
in reducing the burden of treatment on frail patients
undergoing low-risk NMIBC surveillance. One could consider
chemoablation in frail patients presenting with multifocal or
very large papillary tumours prior to TURBT in the
expectation that some will have their tumour burden reduced
at surgery. Our results indicate that a neoadjuvant course of
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intravesical chemotherapy, given over a short period, is well
tolerated and may provide additional therapeutic benefit over
surgical management alone.
In conclusion, low-risk NMIBC management with
chemoablation as an alternative to TURBT is feasible and
safe, but our study did not reach the prespecified level of
complete response. Nevertheless, after chemoablation there
appears to be a sustained reduction in recurrence rate that is
greater than with surgical management alone. Further
research is required to investigate the role and optimal
schedule of neoadjuvant therapy prior to TURBT.
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